Permadoze Oral

Primær information

  • Handelsnavn:
  • Permadoze Oral 1 mg filmovertrukne tabletter
  • Dosering:
  • 1 mg
  • Lægemiddelform:
  • filmovertrukne tabletter
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

Lokation

  • Fås i:
  • Permadoze Oral 1 mg filmovertrukne tabletter
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 57819
  • Sidste ændring:
  • 22-02-2018

Indlægsseddel

Læs denne indlægsseddel grundigt, inden du

begynder at tage dette lægemiddel, da den

indeholder vigtige oplysninger.

– Gem indlægssedlen. Du kan få brug for at læse

den igen.

– Spørg lægen eller apotekspersonalet, hvis der er

mere, du vil vide.

– Lægen har ordineret Permadoze Oral til dig

per son ligt. Lad derfor være med at give medicinen

til andre. Det kan være skadeligt for andre, selvom

de har de samme symptomer, som du har.

– Kontakt lægen eller apotekspersonalet, hvis du får

bivirkninger, herunder bivirkninger, som ikke er

nævnt her. Se punkt 4.

Se den nyeste indlægsseddel på

www.indlægsseddel.dk.

Oversigt over indlægssedlen:

1. Virkning og anvendelse

2. Det skal du vide, før du begynder at tage

Permadoze Oral

3. Sådan skal du tage Permadoze Oral

4. Bivirkninger

5. Opbevaring

6. Pakningsstørrelser og yderligere oplysninger

1. VIRKNING OG ANVENDELSE

Permadoze Oral indeholder B

-vitamin, som er

nødvendigt for nervesystemets funktion og for

dannelsen af røde blodlegemer.

Du kan tage Permadoze Oral til langtidsbehandling af

sygdommen perniciøs anæmi. Det er en alvorlig form

for blodmangel, som skyldes mangel på B

-vitamin.

2. DET SKAL DU VIDE, FØR DU BEGYNDER

AT TAGE PERMADOZE ORAL

Lægen kan have foreskrevet anden anvendelse eller

dosering end angivet i denne information. Følg altid

lægens anvisning og oplysningerne på doserings-

etiketten.

Tag ikke Permadoze Oral, hvis du:

• er overfølsom (allergisk) over for vitamin B

eller

et af de øvrige indholdsstoffer i Permadoze Oral

(angivet i punkt 6).

• har en sjælden, arvelig sygdom i synsnerverne

kaldet Lebers hereditære synsnerveatrofi.

• har nedsat syn på grund af overdrevent tobaks- og

alkoholforbrug.

• har en sjælden sygdom i nervesystemet kaldet

tropisk ataktisk neuropati.

Brug af anden medicin sammen med Permadoze Oral

Fortæl det altid til lægen eller apotekspersonalet, hvis

du bruger anden medicin eller har gjort det for nylig.

Tal med din læge, hvis du tager:

• p-piller.

• medicin mod alvorlige infektioner (aminoglycosider).

• medicin mod kronisk, blødende betændelse i

tarmen (aminosalicylsyre).

• medicin mod epilepsi (phenytoin).

• medicin mod diabetes (metformin).

• medicin mod infektion i øjet (chloramphenicol).

• medicin mod forhøjet kolesterol (colestyramin).

• medicin mod kaliummangel (kaliumsalte).

• medicin mod forhøjet blodtryk (methyldopa).

• medicin mod for meget mavesyre (fx omeprazol og

cimetidin).

Brug af Permadoze Oral sammen med mad og drikke

Du skal tage Permadoze Oral med et glas vand.

Graviditet og amning

Hvis du er gravid eller ammer, har mistanke om, at du

er gravid, eller planlægger at blive gravid, skal du

spørge din læge eller apotekspersonalet til råds, før

du tager dette lægemiddel.

Graviditet

Du kan tage Permadoze Oral under graviditet.

Amning

Permadoze Oral går over i modermælken, men det er

ikke sandsynligt, at det vil skade dit barn.

Tal med lægen, hvis du har spørgsmål.

Trafik- og arbejdssikkerhed

Permadoze Oral påvirker ikke arbejdssikkerheden

eller evnen til at færdes sikkert i trafikken.

3. SÅDAN SKAL DU TAGE

PERMADOZE ORAL

Tag altid Permadoze Oral nøjagtigt efter lægens

anvisning. Er du i tvivl, så spørg lægen eller

apotekspersonalet.

Den sædvanlige dosis er 1 tablet dagligt.

Du skal tage Permadoze Oral med et glas vand.

05/2017

Indlægsseddel: Information til brugeren

Permadoze

Oral

1 mg filmovertrukne tabletter

cyanocobalamin

553709P002

Permadoze

Oral svarer til lægemidlet Betolvex

Permadoze

Betolvex

er registrerede varemærker, der tilhører Actavis Group PTC ehf.

Hvis du har taget for mange Permadoze Oral

Kontakt lægen, skadestuen eller apoteket, hvis du

har taget flere Permadoze Oral, end der står i denne

information eller mere end lægen har fore skrevet (og

du føler dig utilpas). Tag pakningen med.

Permadoze Oral giver som regel ingen symptomer ved

overdosering.

Hvis du har glemt at tage Permadoze Oral

Du må ikke tage en dobbeltdosis som erstatning for

den glemte dosis. Fortsæt blot med den sædvanlige

dosis.

Hvis du holder op med at tage Permadoze Oral

Spørg lægen eller apotekspersonalet, hvis der er

noget, du er i tvivl om. Ændring eller stop med

behandlingen bør kun ske i samråd med lægen.

4. BIVIRKNINGER

Dette lægemiddel kan som al anden medicin give

bivirkninger, men ikke alle får bivirkninger.

Alvorlige bivirkninger

Sjældne bivirkninger (det sker hos mellem 1 og

10 ud af 10.000 patienter):

• Pludseligt hududslæt, åndedrætsbesvær og

besvimelse (inden for minutter til timer), pga.

overfølsomhed (anafylaktisk reaktion).

Kan være livsfarligt. Ring 112.

Ikke alvorlige bivirkninger

Sjældne bivirkninger (det sker hos mellem 1 og

10 ud af 10.000 patienter):

• Allergiske reaktioner inklusive udslæt (nældefeber)

og hævelser. Kan være alvorligt. Tal med lægen.

Hvis der er hævelse af ansigt, læber og tunge, kan

det være livsfarligt. Ring 112.

• Feber.

Tal med lægen eller apoteket, hvis en bivirkning er

generende eller bliver værre, eller hvis du får

bivirkninger, som ikke er nævnt her.

Indberetning af bivirkninger

Hvis du oplever bivirkninger, bør du tale med din læge

eller apoteket. Dette gælder også mulige bivirkninger,

som ikke er medtaget i denne indlægs seddel. Du eller

dine pårørende kan også indberette bivirkninger

direkte til Lægemiddel styrelsen via de oplysninger,

der fremgår herunder.

Lægemiddelstyrelsen,

Axel Heides Gade 1, DK-2300 København S

Websted: www.meldenbivirkning.dk

E-mail: dkma@dkma.dk

Ved at indrapportere bivirkninger kan du hjælpe med

at fremskaffe mere information om sikkerheden af

dette lægemiddel.

5. OPBEVARING

• Opbevar Permadoze Oral utilgængeligt for børn.

• Brug ikke Permadoze Oral efter den udløbsdato,

der står på pakningen (efter EXP). Udløbsdatoen

er den sidste dag i den nævnte måned.

• Spørg på apoteket, hvordan du skal bortskaffe

medicinrester. Af hensyn til miljøet må du ikke

smide medicinrester i afløbet, toilettet eller

skraldespanden.

6. PAKNINGSSTØRRELSER OG

YDERLIGERE OPLYSNINGER

Permadoze Oral 1 mg filmovertrukne tabletter

indeholder:

– Aktivt stof: Cyanocobalamin 1 mg.

– Øvrige indholdsstoffer: Mannitol, pregelatineret

stivelse, mikrokrystallinsk cellulose, magnesium-

stearat, stearinsyre, kartoffelstivelse, hypromellose,

macrogol 400, titandioxid (E171) og rød jernoxid

(E172).

Udseende og pakningsstørrelser:

Permadoze Oral er en rund, konveks, lyserød tablet

mærket CCO.

Permadoze Oral fås i pakningsstørrelsen 120 (2x60)

filmovertrukne tabletter.

Indehaver af markedsføringstilladelsen:

Paranova Danmark A/S

Marielundvej 46D, 2730 Herlev

Frigivet af:

Paranova Pack B.V.

Vijzelweg 32, 8243 PM Lelystad,

Holland

Denne indlægsseddel blev sidst revideret

maj 2017.

05/2017

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Product Quest Manufacturing LLC Recalls All Nasal Products and Baby Oral Gels Manufactured at Florida Facility Due to Possible Microbial Contamination

Product Quest Manufacturing LLC Recalls All Nasal Products and Baby Oral Gels Manufactured at Florida Facility Due to Possible Microbial Contamination

Product Quest Manufacturing (“Product Quest”) announced its voluntary recall of Lot# 173089J of CVS Health 12 Hour Sinus Relief Nasal Mist due to a finding of microbial contamination identified as Pseudomonas aeruginosa.

FDA - U.S. Food and Drug Administration

29-8-2018

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Risk to human and animal health related to the presence of 4,15‐diacetoxyscirpenol in food and feed

Published on: Thu, 16 Aug 2018 00:00:00 +0200 4,15‐Diacetoxyscirpenol (DAS) is a mycotoxin primarily produced by Fusarium fungi and occurring predominantly in cereal grains. As requested by the European Commission, the EFSA Panel on Contaminants in the Food Chain (CONTAM) assessed the risk of DAS to human and animal health related to its presence in food and feed. Very limited information was available on toxicity and on toxicokinetics in experimental and farm animals. Due to the limitations in the avai...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

15-8-2018

G Female Oral Tablets

G Female Oral Tablets

G Female Oral Tablets pose a serious risk to your health and should not be taken

Therapeutic Goods Administration - Australia

10-8-2018

FDA approves new treatment for a rare genetic disorder, Fabry disease

FDA approves new treatment for a rare genetic disorder, Fabry disease

FDA approved Galafold (migalastat), the first oral medication for the treatment of adults with Fabry disease.

FDA - U.S. Food and Drug Administration

29-6-2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Medicines Safety Update, Volume 9, Number 2, June 2018

Oral methotrexate dosing, medicines associated with a risk of neuropsychiatric adverse events, and clozapine and gastrointestinal effects

Therapeutic Goods Administration - Australia

25-6-2018

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy

FDA approved Epidiolex (cannabidiol) oral solution, the first drug comprised of an active ingredient derived from marijuana, to treat two rare and severe forms of epilepsy.

FDA - U.S. Food and Drug Administration

7-6-2018

Minister Bruno Bruins (Sport) opent Special Olympics 2018

Minister Bruno Bruins (Sport) opent Special Olympics 2018

Dit weekend worden in de Achterhoek de Special Olympics Nationale Spelen gehouden. Meer dan 2000 sporters met een verstandelijke beperking gaan de strijd aan in 20 takken van sport. Sportminister Bruno Bruins zal de Spelen vrijdagavond officieel openen tijdens een feestelijke ceremonie in Stadion de Vijverberg in Doetinchem. Bruno Bruins: ‘Sporten is gezond en vooral leuk. Ik vind het belangrijk dat iedereen kan sporten en er lol aan beleeft. Dat is ook een belangrijk onderdeel van het sportakkoord dat i...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

6-6-2018

Philippe Reignault appointed Director of the Plant Health Laboratory and Director of Plant Health at ANSES

Philippe Reignault appointed Director of the Plant Health Laboratory and Director of Plant Health at ANSES

On 4 June, Philippe Reignault was appointed Director of the ANSES Plant Health Laboratory and will also take over from Charles Manceau as Director of Plant Health, with effect from July. Professor of Plant Biology and Diseases at the Littoral Côte d'Opale University since 2010 and Chair of ANSES's Expert Committee on Plant Health since 2012, he will now be responsible for overall coordination of ANSES's scientific work in plant health and protection.

France - Agence Nationale du Médicament Vétérinaire

31-5-2018

LFIT Anatomic CoCr V40 Femoral Heads

LFIT Anatomic CoCr V40 Femoral Heads

Hazard alert - potential for components to separate

Therapeutic Goods Administration - Australia

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

23-5-2018

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

FDA takes action against the use of OTC benzocaine teething products due to serious safety risk, lack of benefit

OTC oral health products containing benzocaine for the temporary relief of sore gums due to teething in infants or children should no longer be marketed. FDA is asking companies to stop selling these products for such use and requesting that companies add new warnings to all other benzocaine oral health products to describe certain serious risks.

FDA - U.S. Food and Drug Administration

23-5-2018

Oral Over-the-Counter Benzocaine Products: Drug Safety Communication  - Risk of Serious and Potentially Fatal Blood Disorder

Oral Over-the-Counter Benzocaine Products: Drug Safety Communication - Risk of Serious and Potentially Fatal Blood Disorder

Oral over-the-counter benzocaine products should not be used to treat infants and children younger than 2 years and should only be used in adults and children 2 years and older if they contain certain warnings on the drug label.

FDA - U.S. Food and Drug Administration

22-5-2018

Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics

Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics

FDA is taking safety actions regarding over-the-counter benzocaine oral drug products and prescription local anesthetics.

FDA - U.S. Food and Drug Administration

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

6-7-2017

The European Commission's decision concerning veterinary medicinal products containing zinc oxide

The European Commission's decision concerning veterinary medicinal products containing zinc oxide

On 26 June 2017, the European Commission adopted a decision to withdraw all marketing authorisations for veterinary medicinal products containing zinc oxide administered orally to food producing species. The medicinal products affected by the decision appear from Annex I to the decision.

Danish Medicines Agency

1-4-2014

Danish Pharmacovigilance Update 27 February 2014

Danish Pharmacovigilance Update 27 February 2014

In this issue of Danish Pharmacovigilance Update: Further restrictions on the use of osteoporosis medicine strontium ranelate (Protelos®), Anticoagulant therapy to be stopped before initiating treatment with the new oral anticoagulants (NOACs).

Danish Medicines Agency

17-2-2014

Danish Pharmacovigilance Update 19 December 2013

Danish Pharmacovigilance Update 19 December 2013

In this issue of Danish Pharmacovigilance Update: Patients with mechanical heart valves should not be treated with the new oral anticoagulants Pradaxa®, Xarelto® and Eliquis®.

Danish Medicines Agency

5-12-2017

Rabitec (IDT Biologika GmbH)

Rabitec (IDT Biologika GmbH)

Rabitec (Active substance: Rabies vaccine (live, oral) for foxes and raccoon dogs) - New authorisation - Commission Decision (2017)1365 of Tue, 05 Dec 2017 European Medicines Agency (EMA) procedure number: EMEA/V/C/4387

Europe -DG Health and Food Safety